Buffalo Wild Wings, Gilead Sciences, Vertex Pharmaceuticals Downgraded

Analysts downgraded and cut price targets on Buffalo Wild Wings (BWLD), Gilead Sciences, Inc. (GILD), and Valeant Pharmaceuticals Intl Inc (VRX)

Feb 8, 2017 at 9:50 AM
facebook X logo linkedin


Analysts are weighing in on sports bar Buffalo Wild Wings (NASDAQ:BWLD), as well as drug stocks Gilead Sciences, Inc. (NASDAQ:GILD) and Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Here's a quick roundup of today's bearish brokerage notes on BWLD, GILD, and VRX.

Earnings Miss Blasts Buffalo Wild Wings

Fresh off a disappointing earnings report, BWLD is down 2.2% at $146.45. Adding insult to injury, no fewer than five analysts cut their price targets on the stock. The shares have been struggling on the charts since topping out at an early December annual high of $175.10. It appears short sellers placed well-time bets on Buffalo Wild Wings, too. During the most recent reporting period, short interest on the restaurant stock spiked 15.8%, and now accounts for a substantial 9.2% of its total float.

Gilead Sciences Stock Succumbs to Bearish Outlook

GILD's earnings report came in better than expected, but its woeful 2017 guidance is hitting the shares. The stock also faces pressure from a raft of negative analyst notes, with Jyske Bank lowering its opinion to "buy" from "strong buy," and Citigroup downgrading its rating to "neutral" from "buy." The latter was one of at least 10 brokerage firms to slice its price target on Gilead Sciences, Inc., as well. Out of the gate, the stock has plunged 9% at $66.54 -- and earlier hit a fresh two-year low at $65.81, in line with our recent prediction. Additional downgrades are a definite possibility, with 12 of 20 analysts rating GILD a "buy" or better, and not a single one sporting a "sell" assessment.

Stifel Cuts Price Target on Slumping Valeant Stock

VRX is up 1% at $14.39, despite a price-target cut to $45 from $50 at Stifel. On a longer-term basis, though, the shares have surrendered over four-fifths of their value in the past year. Understandably, near-term open interest levels are stacked on the put side of the aisle. Valeant Pharmaceuticals Intl Inc sports a Schaeffer's put/call open interest ratio (SOIR) of 1.11, resting just 5 percentage points from a 12-month peak.

Get a jump-start on the day's stock market news with Schaeffer's free Opening View newsletter.
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI